Short Interest in Taiwan Liposome Company, Ltd. (NASDAQ:TLC) Declines By 24.0%

Share on StockTwits

Taiwan Liposome Company, Ltd. (NASDAQ:TLC) was the recipient of a large drop in short interest in April. As of April 15th, there was short interest totalling 1,900 shares, a drop of 24.0% from the March 31st total of 2,500 shares. Based on an average daily volume of 26,800 shares, the days-to-cover ratio is currently 0.1 days.

A hedge fund recently bought a new stake in Taiwan Liposome stock. Renaissance Technologies LLC acquired a new stake in Taiwan Liposome Company, Ltd. (NASDAQ:TLC) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 15,400 shares of the company’s stock, valued at approximately $68,000. 0.22% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:TLC opened at $5.54 on Tuesday. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.06 and a quick ratio of 4.06. The business has a 50-day moving average of $5.78 and a two-hundred day moving average of $5.02. The stock has a market capitalization of $233.11 million, a P/E ratio of -6.92 and a beta of 1.02. Taiwan Liposome has a fifty-two week low of $4.07 and a fifty-two week high of $12.65.

Separately, Zacks Investment Research lowered Taiwan Liposome from a “hold” rating to a “sell” rating in a research note on Friday, February 12th.

About Taiwan Liposome

Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX active drug loading technology enables the potential for reduced dosing frequency and enhanced distribution of liposome-encapsulated APIs to the desired site.

Featured Article: Why do analysts give a neutral rating?

Receive News & Ratings for Taiwan Liposome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taiwan Liposome and related companies with's FREE daily email newsletter.